Mechanism and treatment of motoneuron degeneration in ALS: What have SOD1 mutants told us?

被引:20
作者
Xu, ZS
机构
[1] Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Toxicol, Worcester, MA 01655 USA
[2] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA
[3] Univ Massachusetts, Sch Med, Neurosci Program, Worcester, MA 01655 USA
来源
AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS | 2000年 / 1卷 / 04期
关键词
neurodegenerative disease; superoxide dismutase; spinal cord; paralysis; degeneration;
D O I
10.1080/14660820050515052
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes motoneuron degeneration, skeletal muscle atrophy, paralysis and death. The identification of mutations in Cu,Zn superoxide dismutase (SOD1) as genetic cause of this disease has led to the creation of a number of in-vitro and in-vivo models. Experiments have been carried out in these model systems to address fundamental questions related to the disease: (1) what is the nature of toxicity of the mutated SOD1? (1) what are the cellular targets and pathways that lead to neuronal degeneration? (3) what makes motoneurons particularly vulnerable to the toxicity of the mutant enzyme? and (4) are there effective treatments for ALS based on current hypotheses regarding the disease mechanism? Current research on these questions is reviewed.
引用
收藏
页码:225 / 234
页数:10
相关论文
共 131 条
[1]   Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis [J].
Almer, G ;
Vukosavic, S ;
Romero, N ;
Przedborski, S .
JOURNAL OF NEUROCHEMISTRY, 1999, 72 (06) :2415-2425
[2]   Oxidative damage in neurodegenerative diseases [J].
Beal, MF .
NEUROSCIENTIST, 1997, 3 (01) :21-27
[3]   ALS, SOD AND PEROXYNITRITE [J].
BECKMAN, JS ;
CARSON, M ;
SMITH, CD ;
KOPPENOL, WH .
NATURE, 1993, 364 (6438) :584-584
[4]   A CONTROLLED TRIAL OF RILUZOLE IN AMYOTROPHIC-LATERAL-SCLEROSIS [J].
BENSIMON, G ;
LACOMBLEZ, L ;
MEININGER, V ;
BOUCHE, P ;
DELWAIDE, C ;
COURATIER, P ;
BLIN, O ;
VIADER, F ;
PEYROSTPAUL, H ;
DAVID, J ;
MALOTEAUX, JM ;
HUGON, J ;
LATERRE, EC ;
RASCOL, A ;
CLANET, M ;
VALLAT, JM ;
DUMAS, A ;
SERRATRICE, G ;
LECHEVALLIER, B ;
PEUCH, AJ ;
NGUYEN, T ;
SHU, C ;
BASTIEN, P ;
PAPILLON, C ;
DURRLEMAN, S ;
LOUVEL, E ;
GUILLET, P ;
LEDOUX, L ;
ORVOENFRIJA, E ;
DIB, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) :585-591
[5]   Glutamate in neurologic diseases [J].
Bittigau, P ;
Ikonomidou, C .
JOURNAL OF CHILD NEUROLOGY, 1997, 12 (08) :471-485
[6]  
Bogdanov MB, 1998, J NEUROCHEM, V71, P1321
[7]   Immunocytochemical distribution of ionotropic glutamate receptor subunits in the spinal cord of the rabbit [J].
Bonnot, A ;
Corio, M ;
Tramu, G ;
Viala, D .
JOURNAL OF CHEMICAL NEUROANATOMY, 1996, 11 (04) :267-278
[8]   SUPEROXIDE-DISMUTASE-1 SUBUNITS WITH MUTATIONS LINKED TO FAMILIAL AMYOTROPHIC-LATERAL-SCLEROSIS DO NOT AFFECT WILD-TYPE SUBUNIT FUNCTION [J].
BORCHELT, DR ;
GUARNIERI, M ;
WONG, PC ;
LEE, MK ;
SLUNT, HS ;
XU, ZS ;
SISODIA, SS ;
PRICE, DL ;
CLEVELAND, DW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (07) :3234-3238
[9]   SUPEROXIDE-DISMUTASE-1 WITH MUTATIONS LINKED TO FAMILIAL AMYOTROPHIC-LATERAL-SCLEROSIS POSSESSES SIGNIFICANT ACTIVITY [J].
BORCHELT, DR ;
LEE, MK ;
SLUNT, HS ;
GUARNIERI, M ;
XU, ZS ;
WONG, PC ;
BROWN, RH ;
PRICE, DL ;
SISODIA, SS ;
CLEVELAND, DW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (17) :8292-8296
[10]   SUPEROXIDE-DISMUTASE ACTIVITY, OXIDATIVE DAMAGE, AND MITOCHONDRIAL ENERGY-METABOLISM IN FAMILIAL AND SPORADIC AMYOTROPHIC-LATERAL-SCLEROSIS [J].
BOWLING, AC ;
SCHULZ, JB ;
BROWN, RH ;
BEAL, MF .
JOURNAL OF NEUROCHEMISTRY, 1993, 61 (06) :2322-2325